ABSTRACT
INTRODUCTION
Ventricular arrhythmias, ventricular tachycardia (VT) and ventricular fibrillation (VF), are life-threatening complications of myocardial infarctions and are associated with increased post-myocardial infarction morbidity and mortality (1) . More specifically, VTs more than 48 hours after AMI, consisting of 4 successive beats or more, are associated with an increased prevalence of sudden cardiac death (2) (3) (4) . Although several studies already have already shown that prophylactic therapy with an implantable cardioverter-defibrillator (ICD) leads to an improved survival in patients with left ventricular (LV) dysfunction after a myocardial infarction (2;3;5), only around 35% of the patients receive appropriate ICD therapy during the first 3 years of follow-up (6) . For this reason, additional risk stratification to identify the patients at risk of developing ventricular arrhythmias is necessary.
Prerequisites for the development of ventricular arrhythmias are an arrhythmogenic substrate, triggering factors and facilitating conditions (7) . A suitable arrhythmogenic substrate for ventricular arrhythmias contains a unidirectional pathway for re-entry, a short refractory period and a decreased impulse conduction velocity. Myocardial infarctioninduced scar tissue formation can induce these disturbances in the myocardium and their association with an increase in adverse events has already been shown (8;9) . While the infarcted myocardium consists of non-viable, necrotic tissue, the surrounding border zone -or penumbra-consists of a heterogeneous collection of necrotic, ischemic and viable myocytes, oedema and fibroblasts, which can theoretically provide suitable conditions for the development of arrhythmias (10;11) .
We hypothesize that in the subacute phase after revascularized AMI, a larger proportion of penumbra provides more suitable conditions for arrhythmogenesis and increases the susceptibility to ventricular arrhythmias. Cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE) is a safe, reliable and feasible non-invasive method of assessing and quantifying structural damage to the myocardium (12;13) . This study therefore investigates the association of the LGE-measured penumbra size around the infarcted area, and the development of VTs.
METHODS

Between August 2005 and April 2008 the HEBE trial was performed, in which 200
patients between 30 and 75 years old with a large first ST-elevated myocardial infarction, successfully treated with primary PCI, were included (14) . This study is a selection of the patients from this trial. The study was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by Institutional Review Boards of the participating institutes. The HEBE study design and main results have been published previously (14;15) .
In short, all participating patients received standard medical therapy according to the current guidelines. After giving informed consent, the patients were randomly assigned in a 1:1:1 ratio to a control group (standard medical therapy only), or additional treatment with either intracoronary infusion of autologous bone marrow mononuclear cells (BMMC) or autologous peripheral blood mononuclear cells (PBMC). To evaluate the likelihood of increased ventricular arrhythmia after BMMC and PBMC infusion, resting ECG and 24-hour ambulant ECG recording (Holter monitoring) were acquired 1 month after primary PCI. In addition, clinical follow-up data were obtained at 4 and 12 months, consisting of clinical status and the occurrence of major adverse events (i.e. cardiac death or severe arrhythmic events). A severe arrhythmic event was defined as any event consisting of either sudden cardiac death or documented ventricular arrhythmias for which external defibrillation or implantable cardioverter-defibrillator (ICD) therapy was required. We have previously demonstrated that cell infusion does not predispose to ventricular arrhythmia or unfavourable outcome (16) . In this study, we evaluated the prevalence of VTs in relation to cardiac function and CMR-measured infarct tissue characteristics.
Cardiac magnetic resonance imaging
In all participating patients, CMR was performed between 2 and 7 days after PCI in a clinical 1.5 Tesla MR-scanner (Siemens, Erlangen, Germany; Philips, Best, the Netherlands; GE Healthcare, Waukesha (WI), United States) with the use of a phased array cardiac receiver coil. Functional imaging was performed by using retrospectively ECG-gated steady-state free precession cine imaging with breath-holding. Standard 3 long axis images (4-, 3-and 2-chamber view) and short axis images with full LV coverage were obtained (pixel size 1.6x1.9 mm, slice thickness 6.0 mm, slice gap 4.0 mm, TR/ TE 3.2/1.6 ms, flip angle 60º, field of view 256x156 mm, TR 35-50 ms).
After administration of 0.2 mmol/kg Gd-DOTA (Guerbet, Villepinte, France), LGE images were acquired after 10-15 minutes, using a 2-dimensional segmented inversionrecovery gradient-echo pulse sequence, with individual correction of the inversion time to null the signal of normal myocardium (slice thickness 6.0 mm, slice gap 4.0 mm, field of view 360x360 mm, pixel size 1.4x1.4 mm, TR 1250 ms, typical inversion time 250-400ms). Cine and LGE images of each patient were matched by slice position.
Analysis and definitions of CMR parameters
Analysis was performed with dedicated off-line software (MASS v.5.1 2010-EXP beta, Medis, Leiden, the Netherlands). Cine images were analysed as previously described for calculation of volumes and ejection fraction (14) .
Quantification of infarct core and the penumbra was performed on the short axis LGE images by an experienced CMR reader (YvB), blinded to all patient data and outcomes. In the Gadolinium-enhanced area, a region of interest (ROI) was drawn, containing the myocardium with visually the highest signal intensity, while avoiding any microvascular obstruction (MVO), due to its low signal intensity. A second ROI was drawn in an opposite, unenhanced area of myocardium without artefacts. Quantification was performed using the full-width at half-maximum (FWHM) technique (17;18) . The myocardial area containing Gadolinium enhancement was divided into two regions. The myocardium with a signal intensity of >50% of the maximal intensity in the infarct area ROI, which is normally defined as the infarcted area (18) , was defined as the infarct core. The penumbra was defined as tissue located on the mesomyocardial or subepicardial side of the infarcted area, with an intensity of 25-50% of the maximal intensity in the infarct area ROI. The total enhanced area size is the summation of infarct core and penumbra; in regular myocardial infarct quantification, the penumbra is not included in the total infarcted area. MVO was defined as a subendocardial, hypointense recess of myocardium within the enhanced area. When MVO was present, the infarct mass calculations were corrected for the presence of MVO by manually tracing the area of MVO to include it into the infarct core (figure 1). Tissue with intermediate signal intensity at the subendocardial border between MVO and the infarct core was manually assigned to the infarct core area.
The LGE parameters (i.e. amounts of infarct core, penumbra and total enhanced area) were divided by the total left ventricular mass to standardize the values. Secondly, the amounts of infarct core and penumbra were divided by the total amount of enhanced area to calculate the proportion of infarct core and penumbra within the total enhanced area. Short axis mid-ventricular LGE image (a) with subendocardial microvascular obstruction (MVO, arrow) and quantification of infarct core and penumbra (b) using 25-50% and >50% FWHM cut-off values. Due to low signal intensity of MVO, manual delineation of MVO for inclusion in the infarct core was performed. Tissue with intermediate signal intensity at the border of MVO and the enhanced infarct core was manually assigned to the infarct core area as well.
Analysis and definitions of ECG and Holter monitoring
One month after primary PCI, 24-hour Holter monitoring was performed. Verification of the Holter data was performed by a different reader (LR), also blinded to all other patient data and outcomes. Analysis of rhythm and morphology (supraventricular or ventricular) was performed for each individual complex. The total number of premature ventricular complexes (PVCs) and their configuration (single PVCs, doublet PVCs, triplet PVCs, non-sustained VTs and sustained VTs) were corrected for the total recording time, to standardize the mean number of arrhythmias per 24 hours. Any series of 4 or more successive ventricular complexes with a frequency of >100/min was marked as a VT. Together with the Holter monitoring, a resting 12-channel electrocardiogram (ECG) was made to measure QRS width and corrected QT-time (QTc). Simultaneously with the Holter monitoring, sodium and potassium levels were measured to assess whether serum electrolyte concentration disturbances influence the prevalence of ventricular arrhythmias.
Statistical analysis
First, we analysed whether the treatment groups and control differed in functional and infarct size parameters and the amount of ventricular arrhythmias. Secondly, comparisons were made between the patients with and without ventricular arrhythmias for differences in functional and infarct size CMR parameters.
To assess which clinical and CMR parameters were independently associated with ventricular arrhythmias, multivariate analysis was performed. Variables with a p-value of p 0.10 on univariate analysis, or a known relation with VTs (i.e. age, male gender, time between onset of symptoms and primary PCI, the presence of ventricular fibrillation before primary PCI, LAD-related infarction, LV EDVi, ESVi, EF, QRS width and QTc) were entered in a multivariate logistic regression model with a forward selection procedure; variables were entered if p<0.10. All P-values are two-sided and statistical significance was set at p<0.05.
To investigate the relative prognostic importance and the interrelationship of different infarct parameters, the multivariate analyses were repeated, each time including different parameters. The predictive value of each of these models is expressed by the Nagelkerke R 2 (i.e. as a measure of how well the observed outcomes are replicated by the model).
Statistical analysis was done with the Statistical Package for Social Sciences software (SPSS 15.0 for Windows).
RESULTS
All patients with complete paired data sets of CMR and Holter registrations were included in the study. In 38 of the 200 patients, complete data sets were not available;
16 patients had missing CMR, 15 patients had missing Holter data, and in 7 patients, both data sets were missing. CMR data were unavailable due to lack of a CMR scan (n=6), insufficient image quality for cine or LGE analysis (n=15) or due to incorrect image acquisition (n=2). Holter data were missing in 22 cases; the data were either missing or not acquired (n=12), or of insufficient quality for analysis (n=10) due to severe artefacts or incomplete registration. From the remaining 162 patients, 60 patients were randomized to BMMC treatment, 53 to PBMC treatment and 49 to the control group. CMR was performed at a median of 3 days [3-4 days] after primary PCI. Mean age was 56±10 years and 144 patients (87%) were male. The infarct related artery was the LAD in 64% of the cases, RCA in 25% and the LCx in 11%. The three treatment groups had similar baseline demographics, cardiovascular risk factors, medication, CMR and arrhythmia characteristics (appendix 1).
During Holter monitoring at 1 month follow-up, 27 patients (17%) had triplet PVCs during the registration; of these 27 patients, 20 (74%) had monomorph triplets and 5 (19%) had polymorph triplets; in 2 patients (7%), the morphology could not be accurately established. Twenty-nine patients (18%) had VTs on Holter monitoring; of these 29 patients, 26 (90%) had monomorph VTs and 1 patient (3%) had polymorph VTs. In 2 patients (7%), the morphology was difficult to establish due to disturbances. Of all patients, 13 patients (8%) had both triplet PVCs and VT during registration. General characteristics, medication at discharge and characteristics of the Holter monitoring, blood chemistry and CMR of patients with and without VTs are described in table 1.
Cell therapy and arrhythmias
No difference in the prevalence of triplet PVCs was found between the BMMC group and the control group (15% versus 16%, p=0.85), or between the PBMC group and the control group (19% versus 16%, p=0.74) (16) . Similarly, no differences were found in the prevalence of VTs between either the BMMC group and control (15% versus 18%, p=0.64) or between the PBMC group and control (21% versus 18%, p=0.76) (appendix 1).
Cardiac death and severe arrhythmic events
During 1 year follow-up, none of the 162 patients suffered from ventricular fibrillation (VF) and none of the 162 patients had died at 1 year. Three patients received an ICD for primary prevention according to the Guidelines of the European Society of Cardiology (19) . None of the patients received an ICD for secondary prevention.
Of the 38 patients that were excluded due to incomplete data sets, 3 patients had a severe arrhythmic event. One patient of the PBMC group died of VF 13 days after cell therapy; autopsy revealed in-stent thrombosis. Two patients had documented VF and survived; one of these two patients was assigned to the PBMC treatment and developed VF a few hours after cell infusion. The other patient was assigned to the control group and VF occurred 3 days after randomization. After successful resuscitation without sequelae, both patients received an ICD implantation for secondary prevention. No other patients received an ICD. In none of the patients with an ICD, an appropriate ICD discharge was reported.
Infarct mass and penumbra
Patients had a mean total enhanced area size of 31±11% of the total left ventricular mass. Of the total LV mass, 19±9% consisted of infarct core and 11±4% consisted of penumbra. The total enhanced area consisted for 61±11% of infarct core and for 39±11% of penumbra. All the aforementioned infarct parameters were equally distributed amongst the treatment groups (appendix 1).
Patients with VTs had a similar size of penumbra (VT: 11±5% versus no VT: 11±4% of the total left ventricular mass, p=0.92). However, the total enhanced area was significantly smaller in patients with VTs as compared to patients without VTs (VT: 27±12% versus no VT: 32±11% of the total left ventricular mass, p=0.04). Consequently, small infarcts consisted of proportionally larger areas of penumbra (VT: 45±11% versus no VT: 38±11% of the total enhanced area, p=0.002). With decrease in total enhanced area size, the proportional amount of penumbra within the enhanced area increases (Pearson's correlation -0.44, p<0.001). After correcting for the influence of the total enhanced area size, patients with proportionally more penumbra had more often VTs (Odds Ratio [OR] 1.05, 95% confidence interval 1.01-1.10, p=0.02). The infarct parameters in patients with and without VTs are described in table 1.
Univariate analysis showed a significant association between the occurrence of VTs and an episode of VF before revascularization, smaller size of the total enhanced area, the presence of MVO, and a larger proportion of penumbra within the enhanced area (table 1) 
Relative prognostic importance of infarct parameters to predict VTs
To further elucidate the relative prognostic importance and the interrelationship of the different infarct parameters, multiple multivariate analyses were performed including different parameters (table 3) . When the infarct parameters were included in separate logistic regression models together with the presence of VF before primary PCI, the predictive value of the models, as expressed by the Nagelkerke R 2 , was strongest for model 1 including percentage penumbra of total enhanced myocardium (R 2 =0.15) compared to the models including presence of MVO or percentage enhanced myocardium of total LV mass (models 2 and 3). More importantly, the odds ratio of percentage penumbra of enhanced myocardium did not substantially change when presence of MVO and percentage enhanced myocardium of total LV mass were added to the model (model 4), the OR changed from 1.06 (95% CI 1.02-1.10) to 1.05 (95% CI 1.00-1.09). In fact, presence of MVO and percentage enhanced myocardium of total LV mass were no longer associated with the occurrence of VT after adjusting. Thus, these findings suggest that the percentage penumbra of enhanced myocardium is the strongest and most important infarct parameter in relation to the occurrence of VT.
Penumbra and VTs in patients with an LVEF<40%
In patients with an LVEF<40% (n=59), 11 patients (19%) showed a VT on Holter recording. In patients with an LVEF 40% (n=103), 18 patients (18%) showed a VT. The incidence of VTs did not differ significantly between the two subgroups (p=0.84).
There was no interaction between LVEF and percentage penumbra of total enhanced myocardium with regard to the occurrence of VT. In the subgroup of patients with a LVEF of <40% the OR for percentage penumbra of total enhanced myocardium was 1.07 (95% CI 1.01-1.13) compared to 1.06 (95% CI 1.01 -1.11) in the patients with LVEF 40% (p-value for interaction 0.84). 
DISCUSSION
This study focuses on the association and prognostic value of characterizing different regions within the myocardial infarction with LGE CMR imaging and the development of VTs early after AMI. Patients with myocardial enhancement consisting of larger proportions of penumbra showed more often ventricular arrhythmias at 1 month. Moreover, we found that the prevalence of VF before primary PCI is independently associated with the development of ventricular arrhythmias at 1 month.
Cell therapy and arrhythmogenesis
Among the 163 participating patients, no association was found between cell therapy treatment and the prevalence of VTs. However, one should consider that our study is not sufficiently powered to formally answer this question. Increased incidence of arrhythmias after cell therapy has been described in the past, but most of these studies were performed with other cell types than mononuclear cells (i.e. skeletal myoblasts). Also, the delivery method differed (e.g. intramyocardial injection as opposed to intracoronary infusion) (10;11;19) .
Early risk stratification for ventricular arrhythmias
Patients that suffered from VF before primary PCI were at increased risk for developing VTs at 1 month. This supports the theory that not only the ischemic processes due to the coronary occlusion contribute to ventricular arrhythmias, but that other factors (e.g. genetic predisposition and epigenetic phenomena) may facilitate the development of VF in the presence of ischemia (20) . Theoretically, these additional factors may facilitate the development of VF during scar tissue formation as well.
As stated before, the number of ICD-patients with a reduced ejection fraction after a prior myocardial infarction that receives appropriate shock therapy is low (6), while a substantial proportion of these patients receives inappropriate ICD therapy (21) . Although it is known that premature prophylactic ICD therapy (i.e. the first 40 days after myocardial infarction) does not reduce overall mortality (22) , early identification of patients at increased risk of ventricular arrhythmias may assist in determining whether the patient may benefit from prophylactic ICD therapy at a later stage.
The penumbra and ventricular arrhythmias
To the best of our knowledge, this is the first study to show that early after revascularization of an AMI, the proportion of penumbra within the enhanced myocardium is already associated with increased incidence of VTs on Holter monitoring at 1 month. In this penumbra surrounding the infarcted myocardium, strands of healthy and damaged myocytes are interwoven. Hence, this area incorporates the necessary characteristics for arrhythmogenesis (i.e. a unidirectional pathway, short refractory period and decreased impulse conduction velocity) (9) (10) (11) . Additionally, the repair process itself may also facilitate the arrhythmogenesis, as myofibroblasts infiltrate the infarcted area during scar tissue formation. These myofibroblasts can induce ectopic activity and facilitate arrhythmogenesis, in addition to the aforementioned characteristics (23;24) . A recent rabbit study showed that the intermediate density of myofibroblasts in the penumbra increases arrhythmia susceptibility, whereas a high density of myofibroblasts (as found in the infarct core) does not (25) . Visualization of the extent of arrhythmogenic tissue with
LGE-CMR could become a valuable tool to assess the susceptibility for VTs in a safe and non-invasive manner.
CMR and ventricular arrhythmias in the subacute phase after AMI
LGE-CMR has already been proven to be an accurate and reproducible tool for measuring the total infarct size (13;26;27) . Studies in chronic ischemic heart disease already showed that infarct heterogeneity -by discriminating between different zones within the late gadolinium enhanced area-is associated with increased ventricular arrhythmias and mortality (28) (29) (30) . Although the odds ratio of 1.06 may seem low at first, this corresponds to an odds increase of 6% for VT development for each percentage increase in penumbra.
Interestingly enough, MVO was inversely correlated with the occurrence of VTs on Holter. This is most likely caused by the fact that myocardial infarctions that contain MVO are generally larger and contain less arrhythmogenic penumbra around the infarct. Unfortunately, our study population is too small to further assess whether MVO has prognostic value for more severe arrhythmogenic events (sustained VTs, VF, sudden cardiac death).
This study was performed early after AMI, as opposed to the aforementioned studies in chronic myocardial infarction. Based on the general consensus for infarct size calculation, we used the threshold of 50% of the maximal SI of the infarcted area to discriminate between infarct core and surrounding penumbra (18) . Unfortunately, almost no data exists on the pathological justification or validation of any threshold for visualizing the penumbra in acute myocardial infarction. Additionally, no consensus has yet been reached in chronic myocardial infarction. A few studies assessed the penumbra -or border zone-in a chronic myocardial infarction (28-31). Yan et al. were the first to report a relationship between the infarct 'gray zone' and mortality, using a signal intensity threshold between 2SD and 3SD from normal myocardium (29) . Schmidt et al. and Heidary et al., however, defined the border zone as all myocardium with a SI above the maximum SI in the unaffected myocardium (up to 50% of the maximal SI in the infarcted area) (28;31). Roes et al. used a slightly different definition for the border zone, with a signal intensity between 35% and 50% of the maximal SI of the infarcted area (30) . In summary, most of these studies performed in chronic MI chose a lower threshold around half of the range between the threshold of the infarct core area, and the remote, unaffected myocardium. We chose our threshold of 25%; this threshold correlated best with our visual evaluation of the penumbral area as well.
Myocardial tissue characteristics are markedly different in the subacute and chronic phase (32) . In the first 5 days, myocardial tissue shows infiltration of leukocytes, migration of myofibroblasts towards the infarcted area, interstitial oedema, myocardial haemorrhage and necrotic myocytes. In the chronic phase, cellular debris has been cleared, collagen fibrils are deposited and a fibrous scar tissue is formed (32) . Although the histological content of the penumbra surrounding the infarcted core area is markedly different in subacute and chronic myocardial infarction, this study shows that the 'subacute phase'-penumbra already has predictive value for VTs. However, the differences in tissue composition between acute and chronic myocardial infarction give rise to different pharmacodynamic properties of Gadolinium, making an exact comparison for the enhanced area size and the proportion of core and penumbra, difficult (27;33;34) .
Limitations
Although the surrounding of intermediate signal intensity that we call the penumbra shows an association with VTs, one should consider that LGE-CMR at 1.5 Tesla does not show the myocardial tissue at the cellular level. This creates an averaging of the signal for all tissues in each voxel, called partial volume averaging. Due to this partial volume averaging, no distinction can be made between tissue consisting of disorganized mixtures of damaged and viable myocytes, and a border where a sharply demarcated infarction meets unaffected tissue within one voxel. Additionally, the definition for 'infarct penumbra' as used in our study still lacks pathological validation; the exact histological correlate of the penumbra in the subacute phase of AMI should be an area for future studies to explore.
CONCLUSION
Early after myocardial infarction, the proportional amount of penumbra within the Gadolinium-enhanced area is already associated with an increased risk of developing VTs, supporting the theory that the heterogeneous penumbral tissue may be proarrhythmogenic. Thus, non-invasive assessment of infarct tissue characteristics by CMR may assist in identifying patients at risk of developing VTs and improve risk stratification for prophylactic ICD therapy after acute myocardial infarction. 
